Company / Return on Equity (ROE)
LEXICON PHARMACEUTICALS, INC. Return on Equity (ROE) History
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-164.7%
FY2025
5-year range
-164.7% / -50.0%
FY2021-FY2025
Trend
-135.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
LEXICON PHARMACEUTICALS, INC. reports negative total equity of -164.7% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-164.7% in FY2025 with a 10-year CAGR of -103.5%.
Declined from -94.3% to -164.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -103.5pp
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 135.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -1.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -164.7% | -135.8% |
| FY2024 | -69.8% | +25.9% |
| FY2023 | -94.3% | -88.5% |
| FY2019 | -50.0% | +36.3% |
| FY2018 | -78.5% | -4684.8% |
| FY2017 | -1.6% | +95.4% |
| FY2016 | -35.3% | +42.3% |
| FY2015 | -61.2% | -48.1% |
| FY2014 | -41.3% | -5.8% |
| FY2013 | -39.1% | -14.2% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026